XORTX Therapeutics Files August 2024 Report
Ticker: XRTX · Form: 6-K · Filed: Aug 20, 2024 · CIK: 1729214
Sentiment: neutral
Topics: regulatory-filing, 6-K
TL;DR
XORTX filed its monthly update, confirming 20-F reporting. Nothing major, just housekeeping.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on August 20, 2024, to report its activities for the month of August 2024. The filing indicates that the company is a foreign private issuer and will file its annual reports under Form 20-F. The report was signed by CEO Allen Davidoff.
Why It Matters
This filing provides an update on XORTX Therapeutics' regulatory reporting status as a foreign private issuer, confirming their adherence to SEC filing requirements.
Risk Assessment
Risk Level: low — This is a routine filing confirming the company's reporting status and is not indicative of new financial or operational developments.
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- August 20, 2024 (date) — Filing Date
FAQ
What type of SEC filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer.
Who signed the report on behalf of XORTX Therapeutics Inc.?
The report was signed by Allen Davidoff, Chief Executive Officer.
What is the filing date of this report?
The filing date is August 20, 2024.
Does XORTX Therapeutics Inc. file under Form 20-F or Form 40-F?
XORTX Therapeutics Inc. files under Form 20-F.
What is the company's principal business address?
The company's business address is Suite 2400 - 745 Thurlow Street, Vancouver, A1, V6E 0C5.
Filing Stats: 139 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2024-08-20 15:11:54
Filing Documents
- f6k_082024.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 12KB
- 0001171843-24-004866.txt ( ) — 17KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-40858 XORTX Therapeutics Inc. 3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1 Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XORTX Therapeutics Inc. (Registrant) Date: August 20, 2024 By: /s/ Allen Davidoff Name: Allen Davidoff Title: Chief Executive Officer EXHIBIT INDEX 99.1 News release dated August 20, 2024